Merck & Co., Inc. (NYSE:MRK) Shares Sold by Wealthstream Advisors Inc.

by · The Cerbat Gem

Wealthstream Advisors Inc. trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 4.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,438 shares of the company’s stock after selling 122 shares during the period. Wealthstream Advisors Inc.’s holdings in Merck & Co., Inc. were worth $277,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its stake in shares of Merck & Co., Inc. by 16.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 63,101 shares of the company’s stock valued at $7,211,000 after acquiring an additional 8,985 shares during the period. AMF Tjanstepension AB raised its position in Merck & Co., Inc. by 114.2% in the third quarter. AMF Tjanstepension AB now owns 802,384 shares of the company’s stock worth $91,205,000 after acquiring an additional 427,831 shares in the last quarter. M&G Plc acquired a new stake in Merck & Co., Inc. in the 1st quarter valued at about $48,921,000. Crossmark Global Holdings Inc. grew its stake in shares of Merck & Co., Inc. by 30.2% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 246,414 shares of the company’s stock worth $27,983,000 after purchasing an additional 57,106 shares during the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its holdings in shares of Merck & Co., Inc. by 59.8% in the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 485,103 shares of the company’s stock worth $60,056,000 after purchasing an additional 181,520 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

MRK has been the subject of several research reports. Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $125.00 to $110.00 and set an “equal weight” rating for the company in a research note on Friday, November 1st. Evercore ISI upgraded Merck & Co., Inc. to a “strong-buy” rating in a research report on Tuesday, July 30th. Citigroup cut their price objective on Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Wolfe Research raised shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Barclays decreased their price objective on shares of Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a research note on Monday, October 7th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have assigned a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $130.86.

Read Our Latest Report on MRK

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $98.53 on Thursday. The stock has a market capitalization of $249.24 billion, a P/E ratio of 20.66, a P/E/G ratio of 1.41 and a beta of 0.40. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The business has a 50-day moving average of $109.68 and a two-hundred day moving average of $119.35. Merck & Co., Inc. has a fifty-two week low of $97.90 and a fifty-two week high of $134.63.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. The business had revenue of $16.66 billion for the quarter, compared to analyst estimates of $16.47 billion. Merck & Co., Inc. had a net margin of 19.23% and a return on equity of 36.42%. Merck & Co., Inc.’s revenue was up 4.4% compared to the same quarter last year. During the same period last year, the business posted $2.13 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 7.75 EPS for the current fiscal year.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).